Benzocaine studies
This article was originally published in The Tan Sheet
Executive Summary
CHPA's Oral Discomfort Task Group requests FDA meeting by end of April to "facilitate development of a mutually agreeable approach to studying clinically the benefits and use patterns of benzocaine," trade association says in March 22 letter to agency. CHPA will provide FDA with a background document two weeks before meeting containing rationale for the proposed study designs, responses to agency concerns about protocol. CHPA request responds to FDA's Jan. 8 letter, in which agency questioned proposed protocol for testing efficacy of benzocaine and eugenol for toothache relief (1"The Tan Sheet" Jan. 21, 2002, p. 5). Eugenol-related issues "will be addressed separately," CHPA says...
You may also be interested in...
Eugenol Inclusion In Oral Pain Monograph Requires Actual Use Data – FDA
Both a clinical safety trial and an actual use study are necessary to support including eugenol in the oral discomfort (relief) products final monograph, FDA tells the Consumer Healthcare Products Association
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.